Recursion Pharmaceuticals, Inc. (RXRX)
3.445
-0.04
(-1.29%)
USD |
NASDAQ |
Aug 27, 16:00
3.45
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Debt to Equity Ratio : 0.0728 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0728 |
| March 31, 2026 | 0.0706 |
| December 31, 2025 | 0.0689 |
| September 30, 2025 | 0.0787 |
| June 30, 2025 | 0.0958 |
| March 31, 2025 | 0.0995 |
| December 31, 2024 | 0.1048 |
| September 30, 2024 | 0.1728 |
| June 30, 2024 | 0.1538 |
| March 31, 2024 | 0.1271 |
| December 31, 2023 | 0.1093 |
| September 30, 2023 | 0.1175 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.1128 |
| March 31, 2023 | 0.1233 |
| December 31, 2022 | 0.105 |
| September 30, 2022 | 0.1345 |
| June 30, 2022 | 0.1227 |
| March 31, 2022 | 0.1056 |
| December 31, 2021 | 0.0211 |
| September 30, 2021 | 0.0094 |
| June 30, 2021 | 0.0241 |
| March 31, 2021 | 0.0722 |
| December 31, 2020 | 0.0647 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Twist Bioscience Corp. | 0.21 |
| Absci Corp. | 0.0156 |
| Novavax, Inc. | -1.559 |
| Editas Medicine, Inc. | 0.6768 |
| Dyne Therapeutics, Inc. | 0.3323 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.213B |
| Total Liabilities (Quarterly) | 297.66M |
| Shareholders Equity (Quarterly) | 915.00M |
| Current Ratio | 5.034 |
| Net Debt Paydown Yield | 0.27% |